# reload+after+2024-01-20 07:44:08.019802
address1§2505 Meridian Parkway
address2§Suite 100
city§Durham
state§NC
zip§27713
country§United States
phone§919 806 1074
fax§919 806 1146
website§https://www.chimerix.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
fullTimeEmployees§89
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Michael T. Andriole M.B.A.', 'age': 50, 'title': 'CEO, President & Director', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 592949, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Allen S. Melemed M.B.A., M.D.', 'age': 59, 'title': 'Chief Medical Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 605293, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Michelle  LaSpaluto', 'age': 49, 'title': 'Chief Financial Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas J. Riga', 'age': 48, 'title': 'Chief Operating & Commercial Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Jakeman CPA', 'age': 46, 'title': 'VP of Accounting & Finance', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Joshua E. Allen Ph.D.', 'title': 'Chief Technology Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael A. Alrutz J.D., Ph.D.', 'age': 53, 'title': 'Senior VP, General Counsel & Corporate Secretary', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 619503, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Roy W. Ware MBA, Ph.D.', 'title': 'Chief Manufacturing Technology Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Pablo  Lee M.D.', 'title': 'Head of Medical Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§7
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.03
priceToSalesTrailing12Months§73.5352
currency§USD
dateShortInterest§1702598400
forwardEps§-0.82
exchange§NGM
quoteType§EQUITY
shortName§Chimerix, Inc.
longName§Chimerix, Inc.
firstTradeDateEpochUtc§1365687000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§7389e162-7c43-3cdb-be64-0bc435a74d1a
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§5.0
targetMeanPrice§7.0
targetMedianPrice§7.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§12.539
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
